Oncotelic Therapeutics, Inc. (OTCQB: OTLC) is advancing its Sapu003 program and Deciparticle platform as part of a strategy focused on improving the delivery, bioavailability and therapeutic consistency of oncology treatments. The company is leveraging nanotechnology-enabled drug-delivery systems and pharmacokinetic optimization to potentially improve therapeutic outcomes while reducing development risk.
The approach aligns with broader industry trends favoring advanced delivery technologies that may offer faster development timelines and expanded commercial opportunities. As biotechnology companies increasingly explore ways to enhance the performance of existing therapies rather than developing entirely new compounds, Oncotelic is positioning itself at the intersection of oncology, nanomedicine and artificial intelligence.
Oncotelic is pursuing a platform-based model through Deciparticle and its AI-enhanced PDAOAI biomedical infrastructure initiative. Growing investor interest in scalable healthcare platforms has coincided with expansion across related sectors, including advanced drug-delivery systems and AI-driven healthcare innovation. The company joins a group of companies advancing platform-oriented strategies, including Northwest Biotherapeutics (OTCQB: NWBO), Sangamo Therapeutics (OTCQB: SGMO), HIVE Digital Technologies (NASDAQ: HIVE) and Iovance Biotherapeutics (NASDAQ: IOVA).
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents.
The company also leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration. Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens Oncotelic’s position in oncology and rare disease therapeutics.
The full press release is available at https://ibn.fm/EU38X. For more information about Oncotelic, visit the company’s newsroom at https://ibn.fm/OTLC.
